

Special Issue

The Added Role of Phylogenetics in the HIV Prevention Toolbox

Message from the Guest Editor

Inferences from phylogenetics can delineate the structure of transmission networks at an unprecedented detail, providing novel insights into regional epidemic drivers. In 2019, the US Centers for Disease Control and Prevention advanced phylogenetics as an essential ingredient in the design of prevention strategies towards epidemic control by 2030. With this Special Issue, we wish to explore precisely what phylogenetics adds to the HIV prevention toolbox. We welcome articles that describe phylogenetic insights into specific issues, including (1) The influence of route transmission and disease stage in divergent patterns of spread.

(2) The influence of migration and globalization in patterns of viral spread.

(3) The mixing of epidemics in key vulnerable populations.

(4) The evolution of viral epidemics in the era of highly potent therapy (e.g., integrase inhibitors and preexposure prophylaxis).

(5) Variations in the calling of clusters based on selected methodologies and topological cutoffs.

(6) Scientific validity and the ethics of recent publications that predict partners and directionality of transmission.

Guest Editor

Prof. Dr. Bluma G. Brenner

McGill AIDS Centre, McGill University, Montreal, QC, Canada

Deadline for manuscript submissions

closed (15 December 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/59256

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).